Crossref
Randox’s new £400m testing deal explained, and why doctors are concerned
BMJ · 18.11.2026 · 395 · e101499
DOI: 10.1136/bmj-2026-101499 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, online erschienen am 18.11.2026. Verfasst von Elisabeth Mahase. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
The diagnostics company that faced heavy criticism in the covid pandemic has been handed a new multimillion pound deal by the government. Elisabeth Mahase examines the details
Zitieren
APA
Mahase, E. (2026). Randox’s new £400m testing deal explained, and why doctors are concerned. BMJ, 395, e101499. https://doi.org/10.1136/bmj-2026-101499
Vancouver
Mahase E. Randox’s new £400m testing deal explained, and why doctors are concerned. BMJ. 2026;395:e101499. doi:10.1136/bmj-2026-101499
BibTeX
@article{Mahase2026,
author = {Mahase, Elisabeth},
title = {Randox’s new £400m testing deal explained, and why doctors are concerned},
journal = {BMJ},
year = {2026},
volume = {395},
pages = {e101499},
doi = {10.1136/bmj-2026-101499}
}
EUVIMED